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Background: We investigated the effects of spinal and general anaesthesia and surgical tourniquet on acute pain and
early recovery after total knee arthroplasty (TKA).
Methods: Patients (n¼413) were randomised to four parallel groups: spinal anaesthesia with or without tourniquet, and
general anaesthesia with or without tourniquet. The primary outcome was patient-controlled i.v. oxycodone con-
sumption over 24 postoperative hours.
Results: Results from 395 subjects were analysed. Median i.v. oxycodone consumption did not differ between the four
groups (spinal anaesthesia without [36.6 mg] and with tourniquet [38.0 mg], general anaesthesia without [42.3 mg] and
with tourniquet [42.5 mg], P¼0.42), between spinal (37.7 mg) and general anaesthesia (42.5 mg) groups (median difference
e3.1, 95% confidence interval [CI] e7.4 to 1.2, P¼0.15) and between tourniquet and no-tourniquet groups (40.0 vs 40.0 mg,
median difference e0.8, CI e5.1 to 3.5, P¼0.72). Vomiting incidence was higher with spinal than with general anaesthesia
(21% [42/200] vs 13% [25/194], CI 1.05 to 3.1, P¼0.034). The mean haemoglobin decrease was greater without than with
tourniquet (e3.0 vs e2.5 g dl1, mean difference e0.48, CI e0.65 to e0.32, P<0.001). No differences were observed in pain,
pain management, incidences of blood transfusions, in-hospital complications, or length of hospital stay.
Conclusions: For TKA, spinal and general anaesthesia with or without tourniquet did not differ in 24-h postoperative
opioid consumption, pain management, blood transfusions, in-hospital complications, and length of hospital stay.
Vomiting incidence was higher in the spinal than in the general anaesthesia group. Tourniquet use caused smaller
decreases in haemoglobin levels.
Clinical trial registration: EudraCT 2016-002035-15.
Keywords: acute pain; analgesia; general anaesthesia; knee arthroplasty; knee replacement; opioid; spinal anaesthesia;
tourniquetReceived: February 4, 2020; Accepted: 27 March 2020
© 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.
For Permissions, please email: permissions@elsevier.com
1
2 - Palanne et al.Editor’s key points
 Poorly controlled acute pain may have adverse conse-
quences, including delayed recovery and increased
chronic pain. It is important, therefore, to use periop-
erative regimens that provide optimal analgesia with
minimal side-effects.
 Although some current recommendations advocate
using spinal anaesthesia for total knee arthroplasty,
this current RCT found no clear evidence of benefit
compared with general anaesthesia.
 Tourniquet use did not impact on pain and was asso-
ciated with less reduction in haemoglobin levels.
 Current guidelines, which may be based partly on
retrospective database analyses, should reflect these
new RCT findings, taking into account individual pa-
tient characteristics. Longer-term follow-up of pain and
analgesic use would be of additional interest.Severe knee osteoarthritis that is unresponsive to conserva-
tive treatment is effectively managed with total knee arthro-
plasty (TKA).1 This operation is among the most common
inpatient procedures in Europe and the USA.2,3 However, pain
after TKA is intense and often persists for more than 6
months.4 One risk factor for chronic postoperative pain is the
severity of acute pain after surgery.5,6 This encourages efforts
towards maximal postoperative pain treatment. Surgery in-
creases a patient’s risk for becoming a chronic opioid user,
which emphasises the need for well-designed studies exam-
ining pain-reducing perioperative protocols and postoperative
pain management.7,8
The aim of modern fast-track protocols is to reduce the
length of stay and enhance ambulation and general rehabili-
tation without increasing complications and costs.9e11 A sys-
tematic review published in 2016 found only one RCT that
compared the effects of spinal and general anaesthesia on
pain after fast-track TKA.12 In this trial, general anaesthesia
was associated with better outcomes: patients reported less
pain after the sixth postoperative hour, needed considerably
less opioids, and had less nausea, vomiting and dizziness, and
shorter lengths of stay.13 Current recommendations, however,
favour spinal anaesthesia over general anaesthesia for TKA
because of lower rates of complications. Nevertheless, these
recommendations are based on registry studies, and the level
of evidence is low.14e17
A surgical tourniquet is commonly used in TKA.18 Its use is
considered to expedite the operation, facilitate the cementing
of components, provide a better visual surgical field, and
reduce blood loss.19e23 Some studies favour TKA without a
tourniquet because of decreased postoperative pain, reduced
length of stay, and lower rates of complications, such as
thromboembolic events, and skin, soft tissue, and nerve
damage.22e26 Thus, the advantages of tourniquet use remain
controversial.27,28
In this study, we simultaneously investigated three mo-
dalities concerning TKA. Primarily, we aimed to reproduce the
findings of the previous randomised trial regarding the effects
of spinal and general anaesthesia.13 Secondly, we evaluated
the role of the tourniquet on early recovery after TKA. Thirdly,
we investigated whether different combinations of anaes-
thesia and tourniquet regimens would lead to differences in
recovery. We hypothesised that spinal anaesthesia and gen-
eral anaesthesia, the use and absence of a tourniquet, and thecombinations of these would not differ in their effects on early
recovery.Methods
This was a single-centre, open-label, parallel, four-arm RCT. A
detailed study description of this RCT has been published.29
Ethics and trial registration
This study is in agreement with the World Medical Associa-
tion’s Declaration of Helsinki. Helsinki University Hospital’s
Ethics Committee, Surgery (ref: HUS1703/2016; June 8, 2016)
and the Finnish Medicines Agency Fimea (ref: KL72/2016; May
20, 2016) approved this study. Every patient gave written
informed consent. The study was registered to EudraCT (2016-
002035-15; May 12, 2016) according to the instructions of the
Finnish Medicines Agency Fimea.
Participants
Patients undergoing TKA at the publicly funded Arthroplasty
Centre of Helsinki University Hospital, Finland, were eligible
for the study. We included consenting patients, aged 18e75 yr,
with BMI 40 kg m2, ASA physical status class 1e3, severe
knee osteoarthritis (KellgreneLawrence grade 3e4), failure of
conservative treatment, and eligibility for TKA. We excluded
patients with prior major surgery, severe malalignment of the
target knee, or severe flexion or extension deficits. Other rea-
sons for exclusion were contraindication to the study’s
medication or anaesthesia regimen, ongoing use of strong
opioids, and a need for bridging anticoagulation. We excluded
patients who were unable to understand written study infor-
mation in Finnish or Swedish, and patients who were cogni-
tively impaired, under guardianship, or pregnant.29
Randomisation and blinding
A physician not participating in the study created the
numbered, sealed, and non-translucent randomisation enve-
lopes. Each patient was randomised (allocation ratio 1:1:1:1)
into one of the four parallel groups: spinal anaesthesia with
tourniquet, spinal anaesthesia without tourniquet, general
anaesthesia with tourniquet, and general anaesthesia without
tourniquet. The envelopes were opened no more than 2 h
before the surgery by nurses independent of the study.
Blinding the patients or medical staff was not feasible.29
Perioperative care
Subjects were medicated, anaesthetised, operated on, moni-
tored, cared for, and discharged according to a standardised
protocol previously described in detail.29
Spinal anaesthesia was induced with 15 mg isobaric bupi-
vacaine (Bicain spinal 5 mg ml1; Orion, Espoo, Finland), and
patients were lightly sedated with propofol infusion
(maximum of 4 mg kg1 h1). General anaesthesia was
managed with target-controlled infusions of propofol
(Schnider formula, effect site target 4 mg ml1 adjusted to 3e8
mg ml1 to achieve GE Entropy level of 30e50; GE Healthcare
Finland Oy, Helsinki, Finland) and remifentanil (Minto for-
mula, effect site target 1 ng ml1, adjusted to 1e8 ng ml1 ac-
cording to heart rate and blood pressure). At the beginning of
wound closure, general anaesthesia subjects received i.v.
oxycodone 0.1 mg kg1 (ideal body weight [IBW]). In the
Anaesthesia method and tourniquet in knee arthroplasty - 3tourniquet groups, the pressure level of the tourniquet was 250
mm Hg and the maximum usage time was 2 h. Every subject
received i.v. tranexamic acid 1 g and ondansetron 4 mg. Sur-
gery was performed in all cases through midline incision and
medial parapatellar arthrotomywith the cemented Triathlon®
Total Knee System (Stryker, Kalamazoo, MI, USA) with patella
resurfacing. Local infiltration analgesia with ropivacaine (2 mg
ml1, 150 ml), ketorolac (30 mg ml1, 1 ml), and epinephrine
(0.1 mg ml1, 5 ml) was injected with a systematic multi-
puncture technique, followed by ropivacaine (2mgml1 50ml)
injection into the subcutaneous wound edges.
Pain management comprised paracetamol (1 g) and
ibuprofen (400 mg for subjects with IBW lower than 60 kg; 600
mg for subjects with IBW greater than 60 kg; and 800 mg for
subjects younger than 65 yr and IBW greater than 80 kg)
administered three times daily p.o. During the first 24 post-
operative hours, subjects could self-administer i.v. oxyco-
done (maximum of four doses of 0.04 mg kg1 for IBW per
hour, lock-up time 10 min) with a patient-controlled anal-
gesia device (CADD-Legacy® PCA pump; Smiths Medical,
Kent, UK). After discontinuation of patient-controlled anal-
gesia, patients received one oral dose of extended-release
oxycodone (5 mg for subjects with IBW under 50 kg, 10 mg
for subjects with IBW 50e75 kg, and 15 mg for subjects with
IBW greater than 75 kg), and immediate-release oxycodone
was allowed on request (orally 5mg for subjects with IBW less
than 50 kg, 10 mg for subjects with IBW 50e75 kg, and 15 mg
for subjects with IBW exceeding 75 kg, or if unable to digest
the tablets i.m. 4 mg for subjects with IBW less than 50 kg, 8
mg for subjects with IBW 50e75 kg, and 12 mg for subjects
with IBW greater than 75 kg). Oral tramadol (50mg, one to two
tablets) or a combination of paracetamol and codeine (500/30
mg, one to two tablets) commenced from the second post-
operative day for a maximum of three times daily. Oral pre-
gabalin (75e300 mg one to two times a day) was used as
rescue analgesic if the above-mentioned additional
immediate-release oxycodone was not sufficient. The last
rescue method was peripheral insertion of regional anaes-
thesia. The use of rescue methods was based on the anaes-
thesiologists’ assessments.Outcomes
The primary outcome was the cumulative i.v. oxycodone
consumption via a patient-controlled analgesia device during
the first 24 postoperative hours.13,30
Secondary outcomes included pain and nausea in the re-
covery room and 24 h after operation, as assessed by subjects
using a numerical rating scale (NRS; where 0 denotes no pain/
nausea and 10 indicates worst imaginable pain/nausea),
vomiting during the first 24 h, and the use of anti-emetics, oral
oxycodone, and other analgesics, and the need for regional
anaesthesia during the hospital stay. The secondary outcome
measures also comprised differences in preoperative and first
postoperative day haemoglobin values, need for blood trans-
fusions, postoperative in-hospital complications (all identifi-
able aberrations derived from study case report forms and
electronic patient records evaluated by an anaesthesiologist),
and length of hospital stay (defined as the time from the end of
the surgery to discharge). We also documented the time when
the following discharge criteria were fulfilled: pain is under
control with oral medication, patient can urinate, ambulationis safe, surgical wound effusion is minimal, patient un-
derstands the postoperative instructions on care and medi-
cation, patient is able to take care of themselves or appropriate
help is available, and prescriptions for medications and all
documents for benefits are given to the patient.Statistical analyses
We calculated sample sizes (two-tailed tests, alpha 0.05, 80%
power) with parametric methods to compare the mean dif-
ferences between groups and expanded the results by 16% to
adjust for possible non-parametric analyses, as reported in
detail previously.29 For primary outcomemeasures, the results
reported by Harsten and colleagues13 were used to approxi-
mate the opioid consumption of TKA patients. We defined 20%
difference in opioid consumption as clinically significant. The
minimum sample size for nonparametric between two-group
comparisons was calculated as 104 per group. The minimum
sample size for four-group nonparametric overall difference
was calculated as 71 per group. For the NRS, the minimal
clinically significant change was defined as 1.0.31
We expressed the data as means with standard deviations
for normally distributed variables, medians with inter-quartile
ranges for non-normally distributed variables, and fre-
quencies with percentages for categorical variables. For nor-
mally distributed variables, we conducted comparisons
between the four groups with one-way analysis of variance
and Tukey’s method in further pairwise comparisons. Non-
normally distributed variables were analysed using the
KruskaleWallis test and the ManneWhitney U-test with
Bonferroni adjustments in pairwise comparisons. Compari-
sons between two groups (spinal vs general anaesthesia and
with tourniquet vs without tourniquet) were done with the
independent samples t-test and the ManneWhitney U-test.
We examined categorical data with the c2 test or Fisher’s
exact test for comparisons between the four groups, using
Bonferroni adjustments in pairwise group comparisons, and
binary logistic regression in comparisons between two groups.
The results are reported as mean difference (95% confidence
interval [CI]), HodgeseLehmann estimate for median differ-
ence (95% CI), and odds ratio (95% CI).
We also conducted adjusted analyses, as prespecified in the
study protocol.29 We adjusted the comparisons between the
spinal and general anaesthesia groups for the use of the
tourniquet, and the comparisons between the groupswith and
without the tourniquet for the anaesthesia method. We per-
formed adjusted analyses with a linear model for normally
distributed variables, with a stratified ManneWhitney U-test
for non-normally distributed variables, and with logistic
regression for categorical variables.
We did not impute for missing values because of the low
number of missing values. We used SAS 9.4 (SAS Institute Inc.,
Cary, NC, USA) for the stratified ManneWhitney U-test and
IBM SPSS Statistics 25 (IBM Corp., Armonk, NY, USA) for all
other analyses.Results
Subjects, randomisation, and allocation concealment
The study period was from October 3, 2016 to December 23,
2018. We evaluated a total of 2783 knee arthroplasty patients,
and 413 of these signed the informed consent form
Fig 1. CONSORT flow diagram. CONSORT, Consolidated Standards of Reporting Trials.
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Table S1). The number of subjects ultimately analysed was 395
(Consolidated Standards of Reporting Trials [CONSORT] flow
diagram; Fig. 1). Owing to postponed or cancelled surgeries or
cancelled study participation, 15 randomisation envelopes
were opened and discarded without use. Subject characteris-
tics are presented in Table 1. The patients were treated by 15
experienced arthroplasty surgeons and 33 anaesthesiologists.Comparisons of four groups: spinal anaesthesia with
tourniquet, spinal anaesthesia without tourniquet,
general anaesthesia with tourniquet, and general
anaesthesia without tourniquet
The total amount of i.v. oxycodone consumption during the
first 24 h, other pain management, and the pain scores 24 h
after operation were not significantly different among the four
Table 1 Subject characteristics by study group. Values are number (%) unless specified otherwise. ASA, American Society of Anesthesiologists, COPD, chronic obstructive pulmonary
disease; eGFR, estimated glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula; IQR, inter-quartile range; SD, standard deviation. yData
missing from two patients. zData missing from one patient. Sleep apnoea patients also include those with suspected disease.
Characteristic Spinal
anaesthesia
(n ¼ 200)
General
anaesthesia
(n ¼ 195)
No tourniquet
(n ¼ 195)
Tourniquet
(n ¼ 200)
Spinal anaesthesia
without tourniquet
(n ¼ 99)
Spinal anaesthesia
with tourniquet
(n ¼ 101)
General anaesthesia
without tourniquet
(n ¼ 96)
General anaesthesia
with tourniquet
(n ¼ 99)
Age, mean (SD) 64 (7) 64 (7) 64 (7) 64 (7) 63 (8) 64 (7) 65 (7) 63 (7)
Female sex 131 (66) 120 (62) 117 (60) 134 (67) 58 (59) 73 (72) 59 (61) 62 (62)
BMI, mean (SD) (kg m2) 30.7 (4.5) 30.1 (4.3) 30.2 (4.3) 30.6 (4.4) 30.8 (4.4) 30.7 (4.6) 29.7 (4.2) 30.5 (4.3)
Current smoking 26 (13) 19 (10) 23 (12) 22 (11) 13 (13) 13 (13) 10 (10) 9 (9)
Alcohol use (median
doses/week (IQR))
1.0 (0e3.9) 1.0 (0e4.0)y 1.0 (0e4.0)z 1.0 (0e4.0)z 1.5 (0e4.0) 1.0 (0e3.3) 0.5 (0e4.0)z 1.5 (0e5.1)z
Diabetes mellitus 30 (15) 35 (18) 27 (14) 38 (19) 14 (14) 16 (16) 13 (14) 22 (22)
Medication for
hypertension
110 (55) 106 (54) 97 (50) 119 (60) 46 (46) 64 (63) 51 (53) 55 (56)
Coronary artery disease 6 (3) 9 (5) 13 (7) 2 (1) 4 (4) 2 (2) 9 (9) 0
Transient ischemic
attack or stroke
6 (3) 5 (3) 6 (3) 5 (3) 3 (3) 3 (3) 3 (3) 2 (2)
Antithrombotic
medication
38 (19) 43 (22) 43 (22) 38 (19) 18 (18) 20 (20) 25 (26) 18 (18)
Asthma or COPD 30 (15) 24 (12) 27 (14) 27 (14) 14 (14) 16 (16) 13 (14) 11 (11)
Sleep apnoea 18 (9) 21 (11) 15 (8) 24 (12) 8 (8) 10 (10) 7 (7) 14 (14)
eGRF, mean (SD)
(ml min1 1.73 m2)
85 (12) 88 (11) 86 (12) 87 (12) 85 (13) 85 (12) 87 (11) 88 ± 11
Cancer or ongoing
adjuvant treatment
4 (2) 3 (2) 5 (3) 2 (1) 3 (3) 1 (1) 2 (2) 1 (1)
Depression 14 (7) 13 (7) 12 (6) 15 (8) 7 (7) 7 (7) 5 (5) 8 (8)
Reason for operation
Primary osteoarthritis 184 (92) 185 (95) 183 (94) 186 (93) 91 (92) 93 (92) 92 (96) 93 (94)
Rheumatoid or psoriatic
arthritis
9 (5) 3 (2) 6 (3) 6 (3) 4 (4) 5 (5) 2 (2) 1 (1)
Post-traumatic
osteoarthritis
4 (2) 4 (2) 4 (2) 4 (2) 3 (3) 1 (1) 1 (1) 3 (3)
Other 3 (2) 3 (2) 2 (1) 4 (2) 1 (1) 2 (2) 1 (1) 2 (2)
ASA physical status
1 18 (9.0) 18 (9.2) 16 (8.2) 20 (10.0) 8 (8.1) 10 (9.9) 8 (8.3) 10 (10.1)
2 120 (60.0) 124 (63.6) 125 (64.1) 119 (59.5) 63 (63.6) 57 (56.4) 62 (64.6) 62 (62.6)
3 62 (31.0) 53 (27.2) 54 (27.7) 61 (30.5) 28 (28.3 34 (33.7) 26 (27.1) 27 (27.3)
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Table 2 Comparisons of four groups. Values present median [inter-quartile range], number of patients (%), or mean (standard devi-
ation). Patients assessed pain by numerical rating scale (scores 0e10, where 0¼no pain and 10¼worst imaginable pain). *P<0.001 for the
comparison with the general anaesthesia without tourniquet group and the general anaesthesia with tourniquet group. ¥P¼0.043 for
the comparison with the spinal anaesthesia without tourniquet group and P¼0.001 for the comparison with the spinal anaesthesia
with tourniquet group. yP<0.001 for the comparison with the spinal anaesthesia with tourniquet group and the general anaesthesia
with tourniquet group. zP¼0.004 for the comparison with the spinal anaesthesia with tourniquet group and P¼0.002 for the com-
parison with the general anaesthesia with tourniquet group. PCA, patient-controlled analgesia.
Variable n Spinal anaesthesia
without
tourniquet (n ¼ 99)
Spinal anaesthesia
with
tourniquet (n ¼ 101)
General anaesthesia
without
tourniquet (n ¼ 96)
General anaesthesia
with
tourniquet (n ¼ 99)
P-value
I.V. oxycodone by PCA
during the first 24 h
(mg)
395 36.6 [24.0e55.2] 38.0 [26.0e61.6] 42.25 [27.2e63.5] 42.5 [28.6e62.5] 0.42
Oral oxycodone during
hospital stay (mg)
395 30.0 [20.0e40.0] 30.0 [20.0e40.0] 30.0 [20.0e40.0] 30.0 [20.0e40.0] 0.94
Pregabalin given as
rescue analgesic, no.
(%)
395 12 (12.1) 15 (14.9) 8 (8.3) 10 (10.1) 0.51
Femoral nerve or
adductor canal block
placed, no. (%)
395 2 (2.0) 0 0 1 (1.0) 0.38
Pregabalin prescribed/
dose increased upon
discharge, no. (%)
395 6 (6.1) 4 (4.0) 2 (2.1) 5 (5.1) 0.59
Strong opioid
continued after
hospital discharge,
no. (%)
395 3 (3.0) 1 (1.0) 1 (1.0) 0 0.31
Pain in recovery room
at rest
389 0 [0.0e0.0]* 0 [0.0e0.0]* 2.0 [0.0e3.0] 2.0 [0.0e3.6] <0.001
Pain supine at rest 24 h
after operation
395 3.5 (2.1) 3.7 (2.1) 3.1 (2.3) 3.1 (2.3) 0.14
Pain after flexing hip to
45 with straight knee
24 h after operation
395 5.4 (2.7) 5.9 (2.3) 5.1 (2.5) 5.1 (2.3) 0.07
Pain after flexing knee
to 45 24 h after
operation
392 6.3 (2.2) 6.5 (2.1) 5.7 (2.6) 6.2 (2.2) 0.11
Pain after walking 5 m
24 h after operation
376 5.6 (2.2) 5.7 (2.0) 5.1 (2.4) 5.2 (2.3) 0.22
Nausea in recovery
room, no. (%)
394 1 (1.0) 2 (2.0) 6 (6.3) 6 (6.1) 0.11
Nausea 24 h after
operation, no. (%)
394 41 (41.4) 49 (48.5) 32 (33.3) 23 (23.5)¥ 0.002
Patient vomited during
the first 24 h, no. (%)
394 20 (20.2) 22 (21.8) 15 (15.6) 10 (10.2) 0.13
Anti-emetic given after
operation, no. (%)
395 38 (38.4) 43 (42.6) 37 (38.5) 27 (27.3) 0.14
Change in haemoglobin
(postoperative e
preoperative, g dl1)
393 e3.1 (0.86)y e2.5 (0.77) e2.9 (0.81)z e2.5 (0.79) <0.001
Red blood cell
transfusion, no. (%)
395 3 (3.0) 1 (1.0) 1 (1.0) 1 (1.0) 0.70
Time to fulfil hospital
discharge criteria (h)
325 49.0 [46.0e69.0] 49.0 [47.0e69.0] 50.0 [46.0e70.0] 48.0 [45.0e69.8] 0.55
Actual hospital length
of stay (h)
395 54.0 [48.0e72.0] 52.0 [50.0e72.0] 53.0 [49.0e73.0] 52.0 [48.0e72.0] 0.43
6 - Palanne et al.groups (Table 2). The number of patients with nausea (NRS 1)
at the time point of 24 h after surgery was significantly higher
in both spinal anaesthesia groups than in the general anaes-
thesia with tourniquet group (Table 2).
Decreased haemoglobin levels were more profound in the
groups without tourniquet (Table 2), but the need for red blood
cell transfusions did not differ between groups. The incidence
of postoperative in-hospital complications (SupplementaryTable S2a), time to fulfil hospital discharge criteria, and the
actual length of hospital stay were not significantly different
between the groups (Table 2).Spinal vs general anaesthesia comparisons
The cumulative intake of i.v. oxycodone during the first 24 h,
and other pain management, did not differ significantly
Table 3 Spinal vs general anaesthesia comparisons. Values present median [inter-quartile range] or mean (standard deviation) unless
specified otherwise. CI, confidence interval; PCA, patient-controlled analgesia. Patients assessed pain by numerical rating scale (scores
0e10, where 0¼no pain and 10¼worst imaginable pain). P-values are adjusted with use of surgical tourniquet. yHodgeseLehmann
estimate for median difference. zMean difference.
Variable n Spinal
anaesthesia
(n ¼ 200)
General
anaesthesia
(n ¼ 195)
Difference
(95% CI)
Odds ratio
(95% CI)
Unadjusted
P-value
Adjusted
P-value
I.V. oxycodone by PCA
during the first 24 h
(mg)
395 37.7 [25.3e57.4] 42.5 [27.6e62.5] e3.1 (e7.4 to 1.2)y 0.15 0.14
Oral oxycodone during
hospital stay (mg)
395 30.0 [20.0e40.0] 30.0 [20.0e40.0] 0.0 (0.0e5.0)y 0.58 0.58
Pregabalin given as
rescue analgesic, no.
(%)
395 27 (13.5) 18 (9.2) 1.53 (0.82e2.89) 0.18 0.18
Femoral nerve or
adductor canal block
placed, no. (%)
395 2 (1.0) 1 (0.5) 1.96 (0.18e21.8) 0.58 0.58
Pregabalin prescribed/
dose increased upon
discharge, no. (%)
395 10 (5.0) 7 (3.6) 1.41 (0.53e3.8) 0.49 0.49
Strong opioid
continued after
hospital discharge,
no. (%)
395 4 (2.0) 1 (0.5) 3.96 (0.44e35.7) 0.22 0.22
Pain in recovery room
at rest
389 0.0 [0.0e0.0] 2.0 [0.0e3.0] e2.0 (e2.5 to e2.0)y < 0.001 <0.001
Pain supine at rest 24 h
after operation
395 3.6 (2.1) 3.1 (2.3) 0.5 (0.1e0.9)z 0.025 0.025
Pain after flexing hip to
45 with straight knee
24 h after operation
395 5.7 (2.5) 5.1 (2.4) 0.6 (0.1e1.1)z 0.021 0.021
Pain after flexing knee
to 45 24 h after
operation
392 6.4 (2.2) 6.0 (2.4) 0.4 (e0.01 to 0.9)z 0.055 0.053
Pain after walking 5 m
24 h after operation
376 5.7 (2.1) 5.2 (2.3) 0.5 (0.02e0.9)z 0.039 0.039
Nausea in recovery
room e no. (%)
394 3 (2.5) 12 (6.2) 0.23 (0.06e0.83) 0.025 0.025
Nausea 24 h after
operation e no. (%)
394 90 (45.0) 55 (28.4) 2.07 (1.36e3.14) < 0.001 <0.001
Patient vomited during
the first 24 h e no. (%)
394 42 (21.0) 25 (12.9) 1.80 (1.05e3.09) 0.034 0.034
Anti-emetic given after
operation e no. (%)
395 81 (40.5) 64 (32.8) 1.39 (0.92e2.10) 0.11 0.11
Change in haemoglobin
(postoperative e
preoperative, (g dl1)
393 e2.8 (0.86) e2.7 (0.82) e0.1 (e0.3 to 0.1)z 0.30 0.29
Red blood cell
transfusion, no. (%)
395 4 (2.0) 2 (1.0) 1.97 (0.36e10.9) 0.44 0.44
Time to fulfil hospital
discharge criteria (h)
325 49 [46e69] 49 [45e70] 0.0 (e1.0 to 1.0)y 0.84 0.86
Actual hospital length
of stay (h)
395 53 [49e72] 53 [48e72] 0.0 (e1.0 to 2.0)y 0.58 0.56
Anaesthesia method and tourniquet in knee arthroplasty - 7between the spinal and general anaesthesia groups (Table 3).
Subjects in the spinal anaesthesia group reported less pain in
the recovery room, whereas the pain scores 24 h after surgery
were statistically lower in the general anaesthesia group
(Table 3). The difference at 24 h, however, was below the
predefined clinically significant change.
The number of subjects with nausea in the recovery room
was significantly higher in the general anaesthesia group. The
incidence of nausea at the time point of 24 h after surgery, in
contrast, was higher in the spinal anaesthesia group, as wasthe incidence of vomiting within 24 h after operation (Table 3).
The difference in the number of subjects receiving anti-
emetics was non-significant (Table 3).
The decreases in haemoglobin levels and the need for
blood transfusions did not differ between the groups
(Table 3). No difference in the incidence of postoperative in-
hospital complications (Supplementary Table S2b), median
time for fulfilling hospital discharge criteria, and the actual
length of stay (Table 3) between the two groups were
detected.
Table 4 No tourniquet vs tourniquet comparisons. Values presented as median [inter-quartile range] or mean (standard deviation)
unless specified otherwise. Patients assessed pain by a numerical rating scale (scores 0e10, where 0 ¼ no pain and 10 ¼ worst
imaginable pain). P-values are adjusted with anaesthesia method. CI, confidence interval; PCA, patient-controlled analgesia.
yHodgeseLehmann estimate for median difference. zMean difference.
Variable n No tourniquet
(n ¼ 195)
Tourniquet
(n ¼ 200)
Difference
(95% CI)
Odds ratio
(95% CI)
Unadjusted
P-value
Adjusted
P-value
I.V. oxycodone by PCA
during the first 24 h
(mg)
395 40 [26.0e57.5] 40 [27.3e62.0] e0.8 (e5.1 to 3.5)y 0.72 0.71
Oral oxycodone during
hospital stay (mg)
395 30.0 [20.0e40.0] 30.0 [20.0e40.0] 0.0 (0.0e0.0)y 0.77 0.79
Pregabalin given as
rescue analgesic, no.
(%)
395 20 (10.3) 25 (12.5) 0.80 (0.43e1.49) 0.48 0.48
Femoral nerve or
adductor canal block
placed, no. (%)
395 2 (1.0) 1 (0.5) 2.06 (0.19e22.9) 0.56 0.56
Pregabalin prescribed/
dose increased upon
discharge, no. (%)
395 8 (4.1) 9 (4.5) 0.91 (0.34e2.40) 0.85 0.84
Strong opioid
continued after
hospital discharge,
no. (%)
395 4 (2.1) 1 (0.5) 4.17 (0.46e37.6) 0.20 0.20
Pain in recovery room
at rest
389 0.0 [0.0e2.0] 0.0 [0.0e2.1] 0.0 (0.0e0.0)y 0.61 0.65
Pain supine at rest 24 h
after operation
395 3.3 (2.2) 3.4 (2.3) e0.1 (e0.5 to 0.4)z 0.78 0.78
Pain after flexing hip to
45 with straight knee
24 h after operation
395 5.3 (2.6) 5.5 (2.3) e0.2 (e0.7 to 0.3)z 0.36 0.36
Pain after flexing knee
to 45 24 h after
operation
392 6.0 (2.4) 6.4 (2.2) e0.3 (e0.8 to 0.1)z 0.19 0.18
Pain after walking 5 m
24 h after operation
376 5.4 (2.3) 5.5 (2.2) e0.1 (e0.5 to 0.4)z 0.71 0.72
Nausea in recovery
room, no. (%)
394 8 (4.0) 7 (3.6) 0.90 (0.32e2.53) 0.84 0.85
Nausea 24 h after
operation, no. (%)
394 72 (36.2) 73 (37.4) 1.06 (0.70e1.59) 0.80 0.79
Patient vomited during
the first 24 h, no. (%)
394 35 (17.9) 32 (16.1) 1.14 (0.67e1.93) 0.62 0.62
Anti-emetic given after
operation, no. (%)
395 75 (38.5) 70 (35.5) 1.16 (0.77e1.75) 0.48 0.48
Change in haemoglobin
(postoperative e
preoperative, g dl1)
393 e3.0 (0.84) e2.5 (0.78) e0.48 (e0.65 to e0.32)z < 0.001 <0.001
Red blood cell
transfusion, no. (%)
395 4 (2.1) 2 (1.0) 2.07 (0.38e11.5) 0.40 0.40
Time to fulfil hospital
discharge criteria (h)
325 50 [46e70] 49 [46e69] 1.0 (e1.0 to 2.0)y 0.28 0.28
Actual hospital length
of stay (h)
395 54 [49e72] 52 [49e72] 1.0 (e1.0 to 2.0)y 0.36 0.35
8 - Palanne et al.Comparisons between the spinal and general anaesthesia
groups, after adjusting for the use of a tourniquet, revealed
similar results for the adjusted and unadjusted analyses
(Table 3, Supplementary Table S2b).Tourniquet vs no-tourniquet comparisons
The use of i.v. and oral pain medication, rescue analgesia or
regional anaesthesia, and pain scores did not differ at any time
point between the tourniquet and no-tourniquet groups. This
was also the case with the use of anti-emetics and the inci-
dence of nausea and vomiting (Table 4).Haemoglobin decrease was more profound in the no-
tourniquet group (Table 4). None of the subjects received red
blood cell transfusions during the surgery, nor did the groups
differ significantly in their need for postoperative red blood
cell transfusions.
Nodifferenceswerenoted in the incidenceofpostoperative in-
hospital complications (Supplementary Table S2c), median time
for fulfillinghospital dischargecriteria, or theactual lengthof stay.
Comparisons between the tourniquet and no-tourniquet
groups after adjusting for the anaesthesia technique
revealed similar results for the adjusted and unadjusted ana-
lyses (Table 4, Supplementary Table S2c).
Anaesthesia method and tourniquet in knee arthroplasty - 9Discussion
In this prospective, randomised study on 395 subjects under-
going TKA, we did not find a difference in opioid use during the
first 24 postoperative hours, irrespective of the anaesthesia
method or use of the tourniquet. Subjects had no differences
in their need for oral opioids, rescue analgesics, or regional
anaesthesia during the in-hospital period. At 24 h after oper-
ation, spinal anaesthesia subjects reported more pain than
general anaesthesia patients, but these differences failed to
meet clinical relevance (defined a priori as NRS difference
exceeding 1.0).
The incidence of nausea in the recovery room was lower in
the spinal anaesthesia group. Conversely, the incidence of
vomiting and nausea 24 h after operation was lower in the
general anaesthesia group. Despite these differences, the use
of anti-emetics did not differ between anaesthesia groups. The
use of a tourniquet was associated with a lower decrease in
haemoglobin level, but the need for blood transfusions
remained unaffected. The incidence of in-hospital complica-
tions and the length of hospital stay did not differ significantly
in any of the comparisons. Comparison of the four groups
showed no superiority of one anaesthesia and tourniquet
combination over the other.
The strengths of this study include its large sample size and
prospective randomised design. The drop-out rate after
recruitment, at 4.4%, was minimal for a large-scale clinical
trial.32 We used wide-range inclusion criteria to accommodate
as many patients as possible. Our study comprised multiple
doctors, a large staff, had a modern fast-track protocol with
multimodal painmanagement and earlymobilisation, and it is
up to date. Thus, we consider the results repeatable and gen-
eralisable, with some limitations, taking into account our
study’s inclusion criteria.
Our study has some limitations. Neither subjects nor
personnel were blinded, as the patient was clearly under
general or regional anaesthesia and the wound obviously
bled or did not bleed during surgery. After surgery,
personnel were instructed not to discuss the anaesthesia
method used or the use of a tourniquet with patients.
Nevertheless, subjects might have exchanged their opinions
with each other, which could have affected patient-reported
outcomes. The recruitment rate of 15% reflects the recruit-
ment difficulties previously described for publicly funded
trials.32 Of all evaluated patients, 57% did not fulfil the
recruitment criteria (21% of patients older than 75 yr), 16%
were not recruited because of organisational reasons (e.g.
study personnel not available), and 12% refused to partici-
pate in the study. Nevertheless, the characteristics of our
study population are in line with average TKA patients in the
Finnish Arthroplasty Register.33 Furthermore, our study was
underpowered for detection of possible differences in the
incidence of rare complications, such as intensive care
admission or mortality (both with a prevalence of 1:100014).
The randomised regimens, however, are all in routine clin-
ical use and have acceptable risk profiles.
Our study had more than three times the number of par-
ticipants compared with the previous randomised trial of 120
patients investigating differences between spinal and general
anaesthesia in TKA.13 We could not verify the advantages (e.g.
opioid-sparing effect) of general anaesthesia, as reported by
this other trial.13 One reason for this difference between the
results could be that the increased sample size decreased the
CI and margin of error.Vomiting has a profound effect on patient experience. It
may delay discharge from the recovery room or hospital and
increase the risk for re-admission.34 Our results are in line
with the other randomised trial concerning the higher inci-
dence of nausea and vomiting in the spinal anaesthesia group
on the first postoperative day.13 This brings into question
whether the current guideline recommendation to use
regional anaesthesia to decrease the risk of postoperative
nausea and vomiting is applicable to TKA patients.35 Further
studies investigating the effect of general vs spinal anaes-
thesia on postoperative nausea and vomiting are warranted.
Our study has some discrepancies with the results from
previous database studies and systematic reviews. For
example, previous studies suggested faster recovery and lower
blood transfusion rates in spinal anaesthesia patients.14,36
This discrepancy may reflect the smaller size of our study,
but one cannot dismiss the considerable methodological
problems associated with retrospective database studies. The
lack of randomisation is themost obvious of these problems. A
lack of information about the reasons why a certain regimen
was chosen for each case is a major confounding factor.
Furthermore, some studies were done before or during the
implementation of modern treatment protocols and may thus
be, at least partially, outdated. The conclusions of the database
studies, however, have been used as the basis of suggested
enhanced recovery protocols and consensus guidelines, even
though the quality of the evidence is low.14,16,17
The use of a tourniquet had no effect on reported pain or
the need for analgesia at any point, nor did it appear to have an
effect on nausea and vomiting. Comparison between patients
operated on with a tourniquet and without a tourniquet
revealed that tourniquet use resulted in a more profound
decrease in haemoglobin loss, as reported in a recent rando-
mised trial conducted by Goel and colleagues21 and in a sys-
tematic meta-analysis by Alcelik and colleagues22
Nevertheless, the need for blood transfusions showed no dif-
ferences, which is consistent with the results of other
studies.23,37 Previous data also suggested that a tourniquet
could increase pain, soft tissue damage, muscle and nerve
damage, skin problems, and length of stay.22,23 In our study,
the tourniquet and no-tourniquet groups did not differ in
terms of pain, opioid consumption, tourniquet-related soft-
tissue complications, falling, and length of stay.
Despite the implementation and development of fast-track
protocols, such as multimodal analgesia, the acute and
chronic postoperative pain occurring after TKA remains a
problem. Postoperative pain results in increases in opioid
consumption, length of stay, patient dissatisfaction, costs, and
burden on the healthcare system and thus negatively affects
the outcomes of TKA.38e40 The vast number of these opera-
tions performed worldwide annually emphasises the impor-
tance of knowing whether one regimen has significant
advantages over the other. This study is, so far, the largest RCT
comparing the effects of spinal and general anaesthesia and
tourniquet use in TKA. Our results concerning early recovery
after TKA indicate that spinal and general anaesthesia, either
with or without a tourniquet, are both acceptable methods.Authors’ contributions
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